Trial Profile
A Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST in Subjects Who Experience ADRs Related to IVIG Infusions
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Conestat alfa (Primary) ; Immunoglobulins
- Indications Common variable immunodeficiency
- Focus Adverse reactions; Therapeutic Use
- 11 Feb 2021 Status changed from recruiting to completed.
- 06 Aug 2019 Planned End Date changed from 1 Sep 2019 to 1 Mar 2020.
- 06 Aug 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.